BPC 157: The peptide with big claims and scant evidence STAT BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York How did BPC 157 become the wellness industry's star peptide? Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law